Skip to content

A randomized, double-blind, placebo-controlled, multicenter clinical trial for the effectiveness and safety of Xuechang Shuxuening injection in the treatment of acute ischemic stroke

A randomized, double-blind, placebo-controlled, multicenter clinical trial for the effectiveness and safety of Xuechang Shuxuening injection in the treatment of acute ischemic stroke

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019755
Enrollment
Unknown
Registered
2018-11-26
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Control group:Placebo(Sterile Water for Injection)+basic treatment

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Conform to the diagnostic criteria of acute ischemic stroke; 2. Belongs to patients with TACIPACILACI in OCSP classification; 3. The disease onset time within 72h; 4. NIH Stroke Scale(NIHSS)scores of 4 to 17; 5. mRS score should 2; 6. Aged 40-80 years; 7. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Brain hemorrhage in the head CT/MRIor hemorrhagic tendency; 2. Patients who were treated with vascular access (such as thrombolysis, arterial thrombectomy, ultra-early thrombus aspiration, and stent angioplasty) after the onset of the disease; 3. Cerebral embolism caused by brain tumor, brain injury, parasitic encephalopathy, metabolic disturbance, rheumatic heart disease, coronary heart disease 4. Patients with other limb dysfunction disorders, such as limp, osteoarthritis, rheumatoid arthritis, gouty; arthritis, etc., may have impaired neurological function; 5. Systolic blood pressure after treatment=180mmHgor fasting blood glucose<2.8mmol/L; 6. For people having severe damage on liver function, whoes ALT or AST levels are 1.5 times higher than normal value; serum creatinine (SCR) was 1.2 times the normal upper limit; 7. Serious disturbance of consciousness or psychiatric patients, unable to cooperate; 8. Pregnancy, or preparing for pregnancy lactating women; 9. Allergy to any ingredients of the test herbs in this trial; 10. The other inappropriate factor which judged by investigator; 11. Still in other clinical trial in 1 month.

Design outcomes

Primary

MeasureTime frame
mRS score;

Secondary

MeasureTime frame
mRS score;National Institutes of Health Stroke Scale;Barthel index;

Countries

China

Contacts

Public ContactXiaogang Li

Peking University Third Hospital

xgangli2002@163.com+86 135 0109 5002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026